Alterations in the human lung proteome with lipopolysaccharide

被引：6

作者：

Bowler R.P. ^{[1
]}

Reisdorph N. ^{[1
]}

Reisdorph R. ^{[1
]}

Abraham E. ^{[2
]}

机构：

[1] Department of Medicine, National Jewish Health, Denver, CO

[2] Department of Medicine, University of Alabama at Birmingham, Birmingham, AL

来源：

BMC Pulmonary Medicine | / 9卷 / 1期

关键词：

Acute Lung Injury; Idiopathic Pulmonary Fibrosis; Protein Spot; Drotrecogin Alfa; Gram Negative Sepsis;

D O I：

10.1186/1471-2466-9-20

中图分类号：

学科分类号：

摘要：

Background: Recombinant human activated protein C (rhAPC) is associated with improved survival in high-risk patients with severe sepsis; however, the effects of both lipopolysaccharide (LPS) and rhAPC on the bronchoalveolar lavage fluid (BALF) proteome are unknown. Methods: Using differential in gel electrophoresis (DIGE) we identified changes in the BALF proteome from 10 healthy volunteers given intrapulmonary LPS in one lobe and saline in another lobe. Subjects were randomized to pretreatment with saline or rhAPC. Results: An average of 255 protein spots were detected in each proteome. We found 31 spots corresponding to 8 proteins that displayed abundance increased or decreased at least 2-fold after LPS. Proteins that decreased after LPS included surfactant protein A, immunoglobulin J chain, fibrinogen-γ, α1-antitrypsin, immunoglobulin, and α2-HS-glycoprotein. Haptoglobin increased after LPS-treatment. Treatment with rhAPC was associated with a larger relative decrease in immunoglobulin J chain, fibrinogen-γ, α1-antitrypsin, and α2-HS-glycoprotein. Conclusion: Intrapulmonary LPS was associated with specific protein changes suggesting that the lung response to LPS is more than just a loss of integrity in the alveolar epithelial barrier; however, pretreatment with rhAPC resulted in minor changes in relative BALF protein abundance consistent with its lack of affect in ALI and milder forms of sepsis. © 2009 Bowler et al; licensee BioMed Central Ltd.

引用

共 59 条

[1]

Bernard G.R., Artigas A., Brigham K.L., Carlet J., Falke K., Hudson L., Lamy M., Legall J.R., Morris A., Spragg R., The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination, Am J Respir Crit Care Med, 149, 3 PART 1, pp. 818-824, (1994)

[2]

Hotchkiss R.S., Karl I.E., The pathophysiology and treatment of sepsis, N Engl J Med, 348, 2, pp. 138-150, (2003)

[3]

Ware L.B., Matthay M.A., The acute respiratory distress syndrome, N Engl J Med, 342, 18, pp. 1334-1349, (2000)

[4]

Sinclair D.G., Braude S., Haslam P.L., Evans T.W., Pulmonary endothelial permeability in patients with severe lung injury. Clinical correlates and natural history, Chest, 106, 2, pp. 535-539, (1994)

[5]

Terada L.S., Oxidative stress and endothelial activation, Crit Care Med, 30, SUPPL., (2002)

[6]

Matthay M.A., Wiener-Kronish J.P., Intact epithelial barrier function is critical for the resolution of alveolar edema in humans, Am Rev Respir Dis, 142, 6 PART 1, pp. 1250-1257, (1990)

[7]

Baker C.S., Evans T.W., Haslam P.L., Measurement of ceruloplasmin in the lungs of patients with acute respiratory distress syndrome: Is plasma or local production the major source?, Respiration, 67, 5, pp. 533-538, (2000)

[8]

Emmett M., Fowler A.A., Hyers T.M., Crowle A.J., Crossed immunoelectrophoretic analysis of ARDS lavage proteins, Proc Soc Exp Biol Med, 184, 1, pp. 83-91, (1987)

[9]

Emmett M., Miller J.L., Crowle A.J., Protein abnormalities in adult respiratory distress syndrome, tuberculosis, and cystic fibrosis sera, Proc Soc Exp Biol Med, 184, 1, pp. 74-82, (1987)

[10]

Bowler R.P., Duda B., Chan E.D., Enghild J.J., Ware L.B., Matthay M.A., Duncan M.W., Proteomic analysis of pulmonary edema fluid and plasma in patients with acute lung injury, Am J Physiol Lung Cell Mol Physiol, 286, 6, (2004)

← 1 2 3 4 5 6 →